MetaCap

Adicet Bio (ACET) vs China Pharma (CPHI)

Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.

Summary

China Pharma (CPHI) has outperformed Adicet Bio (ACET) over the past year, losing 72.6% versus a loss of 77.8%. Over five years, ACET leads with a -98.6% price change compared with -99.8% for CPHI. Adicet Bio is the larger company by market cap ($20.0 million vs $18.9 million), about 1.1 times the size.

Summary generated from market data by MetaCap's automated system. Methodology

Relative performance

ACET-77.78%CPHI-72.60%
+430%+164%-102%
Nov 21, 20251 yearNov 20, 2026
ACET-98.56%CPHI-99.85%
+140%+14%-111%
Nov 15, 20215 yearsNov 16, 2026

Percent change in share price from the first common trading day shown; excludes dividends.

Head-to-head

ACET versus CPHI key metrics
MetricACETCPHI
Share price$2.14$0.4384
Market cap$20.03M$18.86M
1-day change-13.01%-13.00%
YTD return-74.58%-63.77%
1-year return-77.78%-72.60%
5-year return-98.58%-99.84%
EPS (TTM)$-7.53$-0.42
Dividend yield0.00%0.00%
Annual dividend$0.00$0.00
Revenue (latest FY)—$4.14M
Revenue growth (YoY)—-8.49%
Net income (latest FY)$-116.80M$-3.19M
Gross margin—-3.18%
Operating margin—-78.16%
Net margin—-76.91%
52-week high$11.15$19.19
52-week low$2.12$0.38
Distance from 52-week high-80.81%-97.72%
Analyst consensusstrong_buy—
Avg. price target upside+1527.57%—
Average volume271.05K1.60M
Shares outstanding9.36M43.02M
Employees102215
SectorHealth CareHealth Care
IndustryBiotechnology: Pharmaceutical PreparationsBiotechnology: Pharmaceutical Preparations

Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.

About Adicet Bio

ACET stock →

Adicet Bio, Inc., a clinical stage biotechnology company, discovers and develops allogeneic gamma delta T cell therapies for autoimmune diseases and cancer in the United States. The company's lead product candidate, prulacabtagene leucel (prula-cel), is an allogeneic gamma delta T cell therapy expressing a CAR that targets CD20 for the potential treatment of autoimmune diseases.

Health Care · Biotechnology: Pharmaceutical Preparations · 102 employees

About China Pharma

CPHI stock →

China Pharma Holdings, Inc. develops, manufactures, and markets pharmaceutical products for human use in the People's Republic of China.

Health Care · Biotechnology: Pharmaceutical Preparations · 215 employees

ACET vs CPHI FAQ

Which is bigger, Adicet Bio or China Pharma?

Adicet Bio (ACET) is larger, with a market capitalization of $20.03M compared with $18.86M for China Pharma (CPHI).

Which stock has performed better over the past year, ACET or CPHI?

CPHI returned -72.60% over the past 12 months, compared with -77.78% for ACET (price return, excluding dividends). Past performance does not predict future results.

Are Adicet Bio and China Pharma in the same industry?

Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.

More comparisons